SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug combo for head and neck cancer shows early promise
Disease control TerminatedThis early-stage trial tested an experimental drug called xevinapant combined with standard chemotherapy and radiation in people with head and neck cancer who cannot take the usual drug cisplatin. The goal was to find the safest dose of xevinapant. The study was terminated early,…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cancer drug QEQ278 tested in Early-Stage trial
Disease control TerminatedThis early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New cancer drug OC-001 tested in advanced tumors – trial ends early
Disease control TerminatedThis early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cancer drug cocktail trial for head and neck cancer ends early
Disease control TerminatedThis study tested a combination of the experimental drug magrolimab with cetuximab and either pembrolizumab or docetaxel in people with head and neck cancer that had come back or spread. Only 4 people enrolled before the trial was stopped early. The goal was to see if the combo c…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising cancer combo trial halted early – no clear answers yet
Disease control TerminatedThis phase 2 trial tested a new drug called SAR444245 combined with either pembrolizumab or cetuximab in 59 adults with head and neck cancer that had spread or come back. The goal was to see if the combinations could shrink tumors. However, the study was terminated early, so we d…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Virtual implants may save jawbone during cancer radiation
Knowledge-focused TerminatedThis study tested a new planning method to protect areas where dental implants could later be placed in patients receiving radiation for head and neck cancer. Researchers used virtual implant markers on CT scans to adjust radiation doses, aiming to keep implant sites safe without…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase: NA • Sponsor: Institut de cancérologie Strasbourg Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC